Entering text into the input field will update the search result below

Gilead's Surge, And Other News: The Good, Bad And Ugly Of Biopharma

Mar. 02, 2020 7:44 AM ETGilead Sciences, Inc. (GILD)BHVN, SMPQY5 Comments


  • Gilead's stock has seen positive momentum following multiple constructive news.
  • Biohaven's migraine treatment is approved.
  • Sun Pharma gets sued for drug plagiarism.
  • Looking for more stock ideas like this one? Get them exclusively at The Total Pharma Tracker. Get started today »

Biohaven Gets the FDA Nod for Migraine Treatment

Biohaven Pharmaceutical (BHVN) announced that the FDA has given approval to its Nurtec ODT for treating migraine in adults. This oral pill is designed for relieving pain after the starting of migraine headaches. Nurtec ODT is composed of rimegepant and is a part of an upcoming class of migraine therapies known as calcitonin gene-related peptide inhibitors.

Biohaven claims that 86 percent of patients treated with a single dose of Nurtec did not require any migraine rescue medication within 24 hours. Biohaven further claims that a single dose of the drug can offer quick relief from pain and returns the patient to normal functioning within an hour. The newly approved drug is expected to provide stiff competition to Allergan’s (AGN) Ubrelvy, which has the distinction of being the first approved oral CGRP for treating acute migraine.

Biohaven considers the oral and dual application of this drug as its main USP. Biohaven Chief Executive Officer Vlad Coric said, “We think there’s a value-add for payers and patients by not having to pay for two different drugs - one for acute and one for prevention.” The drug is expected to fight for market place with Teva Pharmaceuticals Industries (TEVA) and Novartis’ (NVS) Aimovig. The patients are expected to prefer an oral medication over currently available injectibles. However, such injectable medications require less frequent applications.

It is estimated that there are 39 million migraine sufferers in the United States. The company’s rimegapent clinical program evaluated the drug candidate in more than 3,100 patients. The Phase 3 trial’s most common adverse reaction was nausea, which was experienced by 2 percent of patients. The drug is expected to be available in the market by March 2020. It will be available in ODT form which is orally disintegrating tablet which implies that the tablet

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, we’ve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

This article was written by

Avisol Capital Partners profile picture
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.

If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research

Disclaimer - we are not investment advisors.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (5)

EliasMouawad profile picture
Interesting article...When will Remdisivir be approved ?
ubn profile picture

The trial for anti-HIV drug Lopinavir has finished and Chinese doctors will share the results with the World Health Organization and the international community as soon as possible, said respiratory disease expert Cao Bin at a press conference.

"Two trials for Remdesivir are going on successfully, and as soon as we finish the trials we will be very happy to share the data with the international community," said Cao, who is leading the Remdesivir program.
ubn profile picture
GILD is a low risk high reward buy. However, if GILD does not get a dime and this drug works, I would still be very happy.
Play Remdesivir is a gamble as other than Chinese doctors and few GILD insiders, no one knows how clinical trials really goes on. Giving most patients are in China, it will report first double blind result.

Of course, they can use offshore accounts not bear their names to trade but we don't know if they will do so.

To us, it is a gamble but I don't want to gamble. While the result comes in, panic buy or sell will happen and you cannot close your positions at time you wish.
Flex68 profile picture
"panic buy"
"...you cannot close your positions at time you wish."

Uhm...... what?
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.